Date:11/13/2009

2009 2009 (Unaudited) Assets Current assets: Cash and cash equivalents $14,352,876 $12,352,223 Accounts receivable, net of allowance for doubtful accounts of $172,182 and $171,947 at September 30, 2009 and June 30, 2009, respectively 7,121,470 5,620,519 Inventory 3,686,431 3,808,289 Advance payments 764,307 1,188,115 Loan receivable 293,400 -- Other receivables 201,321 601,912 Other current assets 62,560 81,277 Total current assets 26,482,365 23,652,335 Property and equipment, net 10,014,096 9,642,526 Intangibles, net 14,302,974 12,037,483 Total assets $50,799,435 $45,332,344 Liabilities Current liabilities: Accounts payable and accrued expenses $1,577,677 $1,392,639 Short-term bank loans 1,400,985 1,399,075 VAT taxes payable 475,592 458,930 Income taxes payable 510,250 490,514 Other taxes payable 11,473 11,890 Dividends payable 233,683 325,417 Other current liabilities 341,957 307,934 Total current liabilities 4,551,617 4,386,399 Total liabilities 4,551,617 4,386,399 Equity Stockholders' equity: Common stock, $0.001 par value, 50,000,000
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
2. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
3. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
5. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
6. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
7. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
8. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
9. Endo Pharmaceuticals and LecTec Settle Patent Dispute
10. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
11. Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America